Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $7 | $8 | $6 | $8 |
| Short-Term Investments | $3 | $4 | $6 | $9 |
| Receivables | $42 | $3 | $3 | $2 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $9 | $6 | $5 | $5 |
| Total Curr. Assets | $61 | $20 | $20 | $24 |
| Property Plant & Equip (Net) | $1 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $5 | $6 | -$0 |
| Total NC Assets | $3 | $5 | $6 | $0 |
| Other Assets | $0 | $0 | $0 | $7 |
| Total Assets | $64 | $25 | $26 | $31 |
| Liabilities | – | – | – | – |
| Payables | $2 | $3 | $2 | $2 |
| Short-Term Debt | $14 | $0 | $22 | $13 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | -$13 |
| Other Curr. Liab. | $7 | $2 | $4 | $2 |
| Total Curr. Liab. | $24 | $5 | $29 | $17 |
| LT Debt | $37 | $49 | $26 | $34 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $2 | $2 | $1 | -$0 |
| Total NC Liab. | $39 | $50 | $27 | $34 |
| Other Liabilities | $0 | $0 | $0 | $1 |
| Cap. Leases | $1 | $0 | $0 | $0 |
| Total Liabilities | $62 | $56 | $56 | $52 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $12 | $0 |
| Common Stock | $4 | $4 | $4 | $4 |
| Retained Earnings | $11 | -$15 | -$21 | -$12 |
| AOCI | $0 | -$20 | $0 | $0 |
| Other Equity | -$13 | $0 | -$24 | -$12 |
| Total Equity | $1 | -$31 | -$30 | -$21 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $64 | $25 | $26 | $31 |
| Net Debt | $44 | $41 | $42 | $39 |